ArticleSubstance use & misuse2025
Substance Use Monitoring Among People Who Use Drugs Using a Novel Assay to Test Dried Blood Spot Specimens.
Article in Substance use & misuse, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Dried Matrix Spots for the Determination of Opiates and Opioids: Methodological Advances and Applications.Molecules (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
BACKGROUND AND
aimsThe development of comprehensive strategies to understand emerging trends in substance use is necessary to design effective prevention and harm reduction strategies for people who use drugs (PWUD). Dried blood spots (DBS) can be used as a non-conventional drug testing approach that meets Food and Drug Administration (FDA) accuracy and precision guidelines. DESIGN, SETTING, AND
participantsFrom July 2021 to July 2022, 1,559 PWUD were enrolled at six US syringe service programs (SSP) in Sacramento, California, Ellensburg, Washington, and Missoula, Montana ("Western"), Madison, Wisconsin, New Haven, Connecticut, and Wilmington, North Carolina ("Eastern"). MEASURES: Participants completed a survey on demographic and behavioral characteristics and provided DBS specimens. A novel toxicology assay coupling liquid chromatography and tandem mass spectrometry was developed and used to identify the presence/absence of fentanyl, methamphetamine, xylazine, cocaine, and heroin, along with their metabolites. In this cross-sectional analysis, we describe the prevalence of each substance stratified by SSP.
resultsAmong 1,345 PWUD, methamphetamine was more prevalent in the Western versus Eastern state SSPs (95% vs. 33%). The Eastern state SSPs saw higher prevalence of cocaine, fentanyl, heroin, and xylazine than the Western state SSPs (86% vs. 24%; 41% vs. 11%; 20% vs. 17%; 20% vs. 6%, respectively). Testing positive for more than one substance was common (50%).
conclusionsThese results confirm existing regional differences in substance use. Further research is needed on the logistical implications of DBS and in which public health and research settings they may be useful.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.